WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
If fatigue is a concern during treatment, our tirzepatide fatigue guide addresses this common side effect
This hormone regulates blood sugar, digestion, and appetite," explains Gia Eapen, MD
Participants had a mean age of 38.3 years and were randomized 1:1 to receive subcutaneous semaglutide or placebo once weekly for 30 weeks
Disclaimer This article is intended for educational purposes only and should not be considered medical advice
The prior authorization process is similar, but because its an FDA-approved use, you may have better success
:max_bytes(150000):strip_icc()/Common-Symptoms-From-Taking-a-GLP-1-And-How-to-Manage-Them-9e5bb7cee0484522a50dd9d7ce954cc4.jpg)
